Clinical TrialsSearch results
Number of results: 922
Completed
- A Phase I Dose Escalation and Food Effect Study of Isotretinoin
- Severe acne vulgaris
- Toida Tsuneyuki
- 2022-11-25
Completed
- A PHASE I STUDY OF CASIRIVIMAB AND IMDEVIMAB IN JAPANESE ADULT VOLUNTEERS
- coronavirus disease 2019(COVID-19)
- Nanki Toshihiro
- 2021-03-29
Completed
- A PHASE I, TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF RAY121 IN HEALTHY VOLUNTEERS
- Healthy Volunteer
- Kai Megumi
- 2022-08-04
Completed
- A phase II study of additional effect of palliative radiotherapy combined with immune check point inhibitors plus chemotherapy for patients with advanced non-small-cell lung cancer.
- non-small cell lung cancer
- Imaizumi Kazuyoshi
- 2020-10-27
Completed
- A Phase II study of Durvalumab (MEDI4736) plus carboplatin and etoposide in elderly patients with extensive-stage small-cell lung cancer
- extensive-stage small cell lung cancer
- Koichi Azuma
- 2021-08-05
Completed
- A phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in EGFR-mutated advanced non-small cell lung cancer
- non-small cell lung cancer
- Takayama Koichi
- 2019-07-08
Completed
- A phase II trial of osimertinib for elderly patients with advanced or postoperative recurrent non-small-cell lung cancer
- non-small cell lung cancer
- Takayama Koichi
- 2018-11-14
Completed
- A prospective study of investigating the efficacy of FOLFIRI plus Aflibercept as a 2nd line therapy after progression during FOLFOXIRI plus Bevacizumab in unrescetable / metastatic colorectal cancer (CRC) patients.
- Colorectal Cancer
- Oki Eiji
- 2019-04-18
Completed
- A Randomized, Active-comparator, Observer-blind, Phase I/II/III Study to Demonstrate the Immunogenicity of a Single Booster Dose of DS-5670a in Adults and Elderly Received a Primary Series of Approved COVID-19 Vaccine
- Prevention of infectious disease by SARS-CoV-2
- Inoguchi Akihiro
- 2021-12-28
Completed
- A randomized, participant and investigator-blinded, placebo-controlled, single ascending intravenous and single subcutaneous dose study to assess the safety, tolerability and pharmacokinetics of CMK389 in Japanese healthy participants
- Japanese healthy participants
- Yamada Hiroyuki
- 2022-01-21